Search the record

with Duchenne muscular dystrophy or Friedreich's ataxia, those 800 days or so are time they do not have. This summer, we saw Skyclarys approved for Friedreich's ataxia after a long and exhausting campaign, so I welcome the early access scheme that the Department is devising

approved. What we cannot control is the conduct or participation of the drugs companies. The Deputy will be aware, particularly in relation to Skyclarys, that we were waiting for an extremely long time for the drugs company to submit the different pieces of documentation, including its commercial proposal

Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the combined ataxia clinic at Tallaght University Hospital; the estimated timeframe

Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the Combined Ataxia Clinic at Tallaght University Hospital; the estimated timeframe

Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 due to capacity constraints at the combined ataxia clinic at Tallaght University Hospital; the estimated timeframe

Minister for Health if she is aware of concerns that some people living with Friedreich’s ataxia may face significant delays in accessing skyclarys (omaveloxolone) despite its reimbursement from 1 October 2026 (details supplied); the estimated timeframe within which all eligible patients will have commenced treatment; if additional